Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Intrapatient Cross-over Study to Assess the Efficacy of Oxybutynin Versus Venlafaxine in Reducing Hot Flashes in Women Using Endocrine Therapy After Breast Cancer.

NCT06106529 is registered in ClinicalTrials.gov with Reinier de Graaf Groep as lead sponsor.

NCT NCT06106529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06106529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Intrapatient Cross-over Study to Assess the Efficacy of Oxybutynin Versus Venlafaxine in Reducing Hot Flashes in Women Using Endocrine Therapy After Breast Cancer.
Lead sponsor
Reinier de Graaf Groep
Phase
Phase 3
Overall status
Recruiting
Start date
October 3, 2024
Completion date
January 1, 2029
Enrollment
260 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hot flash due to medication